Management of premature menopause
review
OA: closed
CC0
⤵ 6 in-corpus citations
AI-generated summary
Estrogen replacement therapy is the primary treatment for premature ovarian failure until age 52, with no evidence linking it to increased breast cancer risk in this population.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
There has been some confusion among women and health professionals since the publication of the Women's Health Initiative and Million Women studies about the management of premature ovarian failure (POF). Both studies were undertaken in women aged 50 and over, and cannot be extrapolated to their younger counterparts, who would normally be producing their endogenous estrogen, since they have functioning ovaries. Estrogen-based replacement therapy is the main stay of treatment for women with POF and is recommended at least until the average age of natural menopause (52 years in the UK). This view is endorsed by regulatory bodies such as the Committee on Safety of Medicines (now the Commission on Human Medicines) in the UK. No evidence shows that estrogen replacement increases the risk of breast cancer to a level greater than that found in normally menstruating women, and women with POF do not need to start mammographic screening early unless other risk factors are present, such as family history.
My notes (saved in your browser only)
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (9)
- An update: spontaneous premature ovarian failure is not an early menopause via openalex
- W1507543476 via openalex
- W1972578648 via openalex
- W1991880311 via openalex
- W1998347153 via openalex
- W2109424338 via openalex
- W2115466467 via openalex
- W137975887 via openalex
- W2162137928 via openalex
Cited by (6)
- Hormone Replacement Therapy Versus the Combined Oral Contraceptive Pill in Premature Ovarian Failure: A Randomized Controlled Trial of the Effects on Bone Mineral Density 2016
- A cross-sectional national questionnaire survey assessing the clinical attitudes of members of the British Menopause Society to the management of women with premature ovarian insufficiency 2014
- A service evaluation of women attending the menopause/premature ovarian failure clinic of a tertiary referral centre 2012
- EMAS position statement: Managing the menopause in women with a past history of endometriosis 2010
- Treatment of premature ovarian failure trial: description of an ongoing clinical trial 2010
- Cardiovascular Effects of Physiological and Standard Sex Steroid Replacement Regimens in Premature Ovarian Failure 2009
Source provenance
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- unpaywall
- last seen: 2026-06-02T02:00:03.124865+00:00
License: CC0
· commercial use OK